Date and Time
Location
Boğaziçi University Kandilli Deep Tech Base, Rasathane St. N:104 D:7, 34684 Üsküdar/İstanbul
About this event
Boğaziçi University Life Sciences and Technologies Application and Research Center LifeSci, a bi-monthly seminar series ‘Kandilli Deep Talks’, focusing on current issues and innovations in the field of health and biotechnology, especially for start-ups and SMEs, continues at full speed.
Professor of Medicine at Stanford University, Prof. Utkan Demirci will be with us with his “Translation of Microfluidic Technology for Applications in Medicine” speech.
‘Kandilli Deep Talks’ are organized under the scope of the “Technical Assistance for R&D Support Labs for Life Sciences SMEs towards Global Competitiveness” project, co-financed by the European Union and the Republic of Turkey under the Competitive Sectors Program executed by the Ministry of Industry and Technology.
We invite you to attend our event and be a part of Boğaziçi LifeSci network.
AGENDA (GMT+3)
6.00 – 6.15 pm Welcome Speech
Prof. Cengizhan Öztürk
Industrial Projects Coordinator, Bogaziçi University Center for Life Sciences and Technologies
6.15 – 6.30 pm Overview on the Technical Assistance Project
Dr. Pascal Kahlem
Technical Assistance Project Team Leader
6.30 – 7.00 pm Microfluidic Label-free Sorting Technologies and Their Translation for Applications in Medicine
Prof. Utkan Demirci
Professor, Department of Radiology, Canary Center for Cancer Early Detection at Stanford University School of Medicine
7.00 – 7.15 pm Q&A
7.30 pm Closing
Simultaneous translation will be provided.
Contact: bulifesci.events@sistemglobal.com.tr
Abstract
Micro- and nano-scale technologies can have a significant impact on medicine and biology in the areas of biofabrication, cell manipulation, diagnostics and monitoring. At the convergence of these new technologies and biology, we research for enabling solutions to real-world problems at the clinic. Emerging nano-scale and microfluidic technologies integrated with biology offer innovative possibilities for creating intelligent, mobile, medical tools and devices that could transform diagnostics and monitoring, microrobotics, tissue engineering and regenerative medicine. We will present interesting applications of microfluidic technologies in IVF, cancer detection via the isolation of extracellular vesicles and microswimmers. Some of these innovative microfluidic devices have been translated into FDA approved and CE marked products, where they have been widely used by clinics around the world serving patients.
Bio
Dr. Utkan Demirci is a professor with tenure at Stanford University School of Medicine and serves as the interim director and division chief at the Canary Center for Cancer Early Detection in the Department of Radiology. He also was a faculty member earlier at the Brigham and Women’s Hospital, Harvard Medical School at the Harvard-MIT Health Sciences and Technology division prior to his appointment at Stanford. His group is focused on the development of point-of-care technologies and creating microfluidic platforms for sorting rare cells and exosomes for infectious diseases and cancer. Dr. Demirci is a fellow-elect of the American Institute of Medical and Biological Engineering, elected in 2017. He received his PhD from Stanford University in Electrical Engineering in 2005 as well as M.S. degrees in 2001 in Electrical Engineering, and in Management Science and Engineering in 2005. He has published over 200 peer-reviewed articles, 300 abstracts and proceedings, 24 book chapters and editorials, four edited books, over 25 patents pending or granted, and serves as an editorial board member for various peer-reviewed journals. His group focuses on developing innovative point-of-care technologies and creating microfluidic platforms for cancer with broad applications to multiple diseases. Dr. Demirci’s seminal work in microfluidics has led to the development of innovative platform technologies in medicine. His inventions have been licensed to numerous companies. He has co-founded several startups and serves as advisor to multiple companies including DxNow, LevitasBio, and Koek Biotech. His work has translated into several FDA approved and CE marked technologies used at the clinical settings.